Produktanfrage
Asset Licensing Opportunity
Resources
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Porgaviximab/Larcaviximab/Cosfroviximab | c2G4-N; c4G7; c13C6 | Phase 3 Clinical | Mapp Biopharmaceutical, Public Health Agency Of Canada'S National Microbiology Laboratory | Hemorrhagic Fever, Ebola | Details |
| MIL-77 | MIL-77 | Phase 1 Clinical | Beijing Mabworks Biotech Co Ltd, Zhejiang Hisun Pharmaceutical Co Ltd, Institute Of Basic Medicine Academy Of Military Medical Sciences | Hemorrhagic Fever, Ebola | Details |
Inverkehr gebrachte Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Frühestes Markenname | Frühestes Genehmigungsland | Früheste Indikation | Früheste Genehmigungsgesellschaft | Früheste Genehmigungsdatum | Indikationen | Klinische Studie |
|---|---|---|---|---|---|---|---|---|---|---|
| Ansuvimab | VRC-EBOMAB092-00-AB; MAb114; MAb-114 | Approved | National Institute Of Allergy And Infectious Diseases (Niaid), National Institute of Health, Islamabad | Ebanga | United States | Hemorrhagic Fever, Ebola | Ridgeback Biotherapeutics Lp | 2020-12-21 | Hemorrhagic Fever, Ebola | Details |
| Atoltivimab/Maftivimab/Odesivimab | REGN3470-3471-3479; REGN-EB3 | Approved | Inmazeb | United States | Hemorrhagic Fever, Ebola | Regeneron Pharmaceuticals Inc | 2020-10-14 | Hemorrhagic Fever, Ebola | Details |
Customer Reviews